Name: GLP-3 30mg Peptide - Revvd Research
SKU: RT30
Availability: InStock

Lot #26033RT303

GLP-3 (Retatrutide) 20mg research peptide vial

GLP-3 [30mg]

4.9 / 5

Trusted by 5,000+ researchers

30mg / vial

≥99% HPLC

Triple incretin receptor agonist

GLP-3 [30mg]

30mg / vial

Triple incretin receptor agonist

≥99% HPLC

4.9 / 5

Trusted by 5,000+ researchers

$225.00

30-day money back

2-day shipping

Signed COA on every batch

Secure checkout

Research use only · Not for human or veterinary use

COA on Every Batch

BioRegen Verified

≥99% HPLC Purity

Made in the USA

2-Day Shipping

30-Day Money Back

Researcher-grade specs. No guesswork.

Each vial ships with structural data and lot identifiers for the compound, plus a Certificate of Analysis documenting purity and identity. Ready for the bench. Synthesized via solid-phase peptide synthesis (SPPS), purified by reverse-phase HPLC, verified by mass spectrometry, and tested for sterility and endotoxin load. Every spec is documented on the signed Certificate of Analysis that ships with your vial.

GLP-1 / GIP / Glucagon Triple Agonist Research Compound is a 39-amino acid synthetic peptide that acts as a triple agonist at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors.

The triple receptor agonism of GLP-3 adds hepatic glucagon receptor activation to the incretin-based effects of dual GIP/GLP-1 agonists. Published research has examined hepatic fat oxidation, resting metabolic rate, and energy expenditure pathways associated with this triple-agonist mechanism in preclinical models.

This product is for laboratory research use only. Not for human administration. Not intended to diagnose, treat, cure, or prevent any disease.

Documented Research Areas

Triple GLP-1/GIP/glucagon receptor binding and co-activation in vitro

Hepatic fat oxidation and VLDL secretion modulation via glucagon receptor activation

Body weight and adiposity reduction in diet-induced obesity preclinical models

Energy expenditure and metabolic rate modulation in preclinical metabolic studies

Comparative triple versus dual incretin receptor agonism pharmacology

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA.

Researcher-grade specs. No guesswork.

Each vial ships with structural data and lot identifiers for the compound, plus a Certificate of Analysis documenting purity and identity. Ready for the bench. Synthesized via solid-phase peptide synthesis (SPPS), purified by reverse-phase HPLC, verified by mass spectrometry, and tested for sterility and endotoxin load. Every spec is documented on the signed Certificate of Analysis that ships with your vial.

— Component 01

GLP-3· 30mg

Class

Triple GIP/GLP-1/Glucagon receptor agonist

Sequence

39 aa triple incretin receptor agonist with C18 fatty diacid modification (GIP/GLP-1/Glucagon triple agonist scaffold)

CAS Number

2381089-83-2

Molecular Formula

C₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight

4,731.34 g/mol

Per-component purity

≥ 98%

One compound. One research record.

GLP-1 / GIP / Glucagon Triple Agonist Research Compound is a 39-amino acid synthetic peptide that acts as a triple agonist at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors.

The triple receptor agonism of GLP-3 adds hepatic glucagon receptor activation to the incretin-based effects of dual GIP/GLP-1 agonists. Published research has examined hepatic fat oxidation, resting metabolic rate, and energy expenditure pathways associated with this triple-agonist mechanism in preclinical models.

This product is for laboratory research use only. Not for human administration. Not intended to diagnose, treat, cure, or prevent any disease.

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA.

Documented Research Areas

Triple GLP-1/GIP/glucagon receptor binding and co-activation in vitro

Hepatic fat oxidation and VLDL secretion modulation via glucagon receptor activation

Body weight and adiposity reduction in diet-induced obesity preclinical models

Energy expenditure and metabolic rate modulation in preclinical metabolic studies

Comparative triple versus dual incretin receptor agonism pharmacology

A curated list of published peer-reviewed papers indexed in PubMed where BPC-157 has been studied. Provided for research-context only. Linking to the literature does not constitute endorsement of any therapeutic application.

Jastreboff AM, et al. · N Engl J Med

Triple-Hormone-Receptor Agonist GLP-3 for Obesity — A Phase 2 Trial

PubMed · PubMed · 37366317

Rosenstock J, et al. · Lancet

GLP-3, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active controlled phase 2 trial

PubMed · PubMed · 37366302

Compound database reference for chemical and structural data:

Research You Can Trust.

At Revvd Research, quality comes first. Our peptides are produced using advanced manufacturing processes and verified through comprehensive testing protocols to deliver dependable results for research applications.

Verified Purity

0 %+

Quality Assured

0 %

USA

Produced

Every lot. Every researcher. Same proof.

Each batch ships with a third-party Certificate of Analysis from BioRegen Analytical. HPLC purity, mass-spectrometry identity, sterility, and LAL endotoxin screening. Every test, every lot.

Your lot number ships on the label and on the COA. Enter it in the verifier any time to retrieve the original lab report.

Verify Batch COA

Certificate of Analysis

Compound (GLP-3)

CAS#2381089-83-2

Sequence39 aa triple GIP/GLP-1/glucagon receptor agonist with C18 fatty diacid modification

Molecular FormulaC₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight4,731.34 g/mol

Purity (HPLC)On file

Identity (LC-MS)On file

Sterility / LALPASS

Date TestedOn file

Related compounds.

Other research peptides in the Revvd catalog cited alongside the BPC-157 + TB-500 blend in the published research literature.

GLOW [70mg]

50mg / 10mg / 10mg per vial

CAS#

49557-75-7

Formula

C₁₄H₂₄CuN₆O₄

M.W.

403.9 g/mol

Research use only · Not for human or veterinary use

$80.00

$160

BPC-157 [10mg]

10mg / vial

CAS#

137525-51-0

Formula

C₆₂H₉₈N₁₆O₂₂

M.W.

1,419.55 g/mol

Research use only · Not for human or veterinary use

$40.00

$80

BPC-157 + TB-500 [5mg/5mg]

5mg / 5mg per vial

CAS#

137525-51-0

Formula

C₆₂H₉₈N₁₆O₂₂

M.W.

1,419.55 g/mol

Research use only · Not for human or veterinary use

$47.50

$95

TESAMORELIN + IPAMORELIN [5mg/5mg]

5mg / 5mg per vial

CAS#

218949-48-5

Formula

C₂₂₁H₃₆₆N₇₂O₆₇S

M.W.

5,135.77 g/mol

Research use only · Not for human or veterinary use

$55.00

$110

Write Reviews Here

[wiserrw_product_review]

Answered straight.

GLP3 in the research peptide market. The compound is also commonly referenced as LY3437943 (Eli Lilly’s developmental code), Triple G, or GGG Peptide. We use “GLP3” on the label because it’s the most-searched naming convention among researchers comparing this triple agonist to single-agonist GLP-1 (Semaglutide) and dual-agonist GLP-1/GIP (Tirzepatide) compounds. The underlying compound on the COA and in all references is the same: GLP-3 / LY3437943.

The standard for research integrity.

Featured Collection – Premium purity compounds crafted with consistency, precision, and quality in mind.

Add the GLP-3 [30mg] blend to your research arsenal.

5,000+ researchers trust Revvd for batch-tested peptides. Every vial. Every COA. Every time.

30-day money back · Free shipping over $150 · 2-day shipping

Signed COA on every batch

Lot #26033RT303

GLP-3 [30mg]

4.9 / 5

Trusted by 5,000+ researchers

30mg / vial

≥99% HPLC

Triple incretin receptor agonist

GLP-3 [30mg]

30mg / vial

Triple incretin receptor agonist

≥99% HPLC

4.9 / 5

Trusted by 5,000+ researchers

$225.00

30-day money back

2-day shipping

Signed COA on every batch

Secure checkout

COA on Every Batch

BioRegen Verified

≥99% HPLC Purity

Made in the USA

2-Day Shipping

30-Day Money Back

Researcher-grade specs. No guesswork.

Documented Research Areas

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA.

Researcher-grade specs. No guesswork.

One compound. One research record.

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA.

Documented Research Areas

A curated list of published peer-reviewed papers indexed in PubMed where BPC-157 has been studied. Provided for research-context only. Linking to the literature does not constitute endorsement of any therapeutic application.

Compound database reference for chemical and structural data:

Research You Can Trust.

USA

Every lot. Every researcher. Same proof.

Each batch ships with a third-party Certificate of Analysis from BioRegen Analytical. HPLC purity, mass-spectrometry identity, sterility, and LAL endotoxin screening. Every test, every lot.

Your lot number ships on the label and on the COA. Enter it in the verifier any time to retrieve the original lab report.

Certificate of Analysis

Compound (GLP-3) CAS#2381089-83-2 Sequence39 aa triple GIP/GLP-1/glucagon receptor agonist with C18 fatty diacid modification Molecular FormulaC₂₂₁H₃₄₂N₄₆O₆₈ Molecular Weight4,731.34 g/mol Purity (HPLC)On file Identity (LC-MS)On file Sterility / LALPASS Date TestedOn file

Related compounds.

Other research peptides in the Revvd catalog cited alongside the BPC-157 + TB-500 blend in the published research literature.

GLOW [70mg]

CAS#

Formula

M.W.

$80.00

BPC-157 [10mg]

CAS#

Formula

M.W.

$40.00

BPC-157 + TB-500 [5mg/5mg]

CAS#

Formula

M.W.

$47.50

TESAMORELIN + IPAMORELIN [5mg/5mg]

CAS#

Formula

M.W.

$55.00

Write Reviews Here

Answered straight.

Why is this called GLP3?

Is GLP-3 FDA-approved?

What is the purity of this GLP-3?

Who tests it, and how do I know the results are real?

Where is it manufactured?

How is it shipped?

What's your return policy?

What's included with each vial?

The standard for research integrity.

Add the GLP-3 [30mg] blend to your research arsenal.

5,000+ researchers trust Revvd for batch-tested peptides. Every vial. Every COA. Every time.